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ABSTRACT 
 
Objective: Building phenotype models using electronic health record (EHR) data conventionally requires 
manually labeled cases and controls. Assigning labels is labor intensive and, for some phenotypes, 
identifying gold-standard controls is prohibitive. To facilitate comprehensive clinical decision support and 
research, we sought to develop an accurate EHR phenotyping approach that assesses its performance 
without a validation set.  
Materials and Methods: Our framework relies on specifying a random subset of cases, potentially using 
an anchor variable that has excellent positive predictive value and sensitivity that is independent of 
predictors. We developed a novel maximum likelihood approach that efficiently leverages data from 
anchor-positive and unlabeled patients to develop logistic regression phenotyping models. Additionally, 
we described novel statistical methods for estimating phenotyping prevalence and assessing model 
calibration and predictive performance measures.  
Results: Theoretical and simulation studies indicated our method generates accurate predicted 
probabilities, leading to excellent discrimination and calibration, and consistent estimates of phenotype 
prevalence and anchor sensitivity. The method appeared robust to minor lack-of-fit and the proposed 
calibration assessment detected major lack-of-fit. We applied our method to EHR data to develop a 
preliminary model for identifying patients with primary aldosteronism, which achieved an AUC of 0.99 
and PPV of 0.8. 
Discussion: We developed novel statistical methods for accurate model development and validation with 
minimal manual labeling, facilitating development of scalable, transferable, semi-automated case labeling 
and practice-specific models. 
Conclusion: Our EHR phenotyping approach decreases labor-intensive manual phenotyping and 
annotation, which should enable broader model development and dissemination for EHR clinical decision 
support and research. 
 
BACKGROUND AND SIGNIFICANCE 
The adoption of Electronic Health Records (EHRs) by healthcare systems has the potential to enable 
implementation of comprehensive, computational clinical decision support and clinical research1-4. However, 
EHRs have been designed primarily to support documentation for medical billing rather than being 
intricately embedded in clinical diagnostic processes5-7, so patients’ complex, clinical phenotypes are not 
natively represented in the rich, accurate, precise format that is important for many analyses8-11. To overcome 
this limitation, a variety of heuristic and statistical methods have been developed for phenotyping patients 
based on EHR data12,13. The vast majority of these existing methods require a curated dataset of patients who 
are completely and accurately labeled with regard to the presence or absence of a phenotype. Such methods 
require experts to retrospectively review EHR charts and/or prospectively evaluate patients to label them 
with respect to the phenotype. For many phenotypes, the labor and cost of these processes limit the 
achievable sample size, compromising the accuracy of potential phenotyping methods.  
 
Such approaches can be improved upon by appreciating that clinical practice workflows are often not 
symmetric with regards to cases and controls. In practice, for most diseases, only specific patients are 
actively evaluated based on clinical suspicion. However, the converse is not true; there are very few 
phenotypes for which everyone is actively screened for, so clinical practice data is frequently insufficient to 
identify a set of gold-standard controls. As a result, for many phenotypes, the most readily accessible 
annotations are an incomplete set of gold-standard cases and few or no gold-standard controls. It is highly 
desirable to develop new phenotyping methods that efficiently and accurately leverage such incomplete 
phenotyping, or “positive-only” data. 
 
Within this framework, one special case with extremely desirable consequences is when the labeled cases are 
a random subset of the full set of true cases14. This set of cases could be identified through an active labeling 
process as part of existing clinical care or research. However, a more generalizable strategy that has the 
potential to decrease the requirement for manual chart review is the use of binary “anchor variables”
15
 that 
summarize clinical domain expertise for classifying patients’ phenotype. By definition, an anchor variable 
has perfect positive predictive value (PPV), but is not required to have high sensitivity. That is, anchor 
positivity indicates presence of the phenotype, but anchor negativity is non-deterministic of the true 
phenotype status. The second critically important requirement for an anchor variable is that its sensitivity be 
independent of all phenotype model predictors. An ideal anchor variable is a structured data element in the 
EHR that is only present in cases, such as the result of a diagnostic confirmatory test or an order that only 
follows a definitive diagnosis. For example, a pathologic diagnosis of cancer will in most scenarios have a 
very high PPV, but perhaps an imperfect sensitivity because of variability in practice or documentation, 
variability in diagnostic categories, or data incompleteness. For many phenotypes, such definitive diagnostic 
information may not be available, so surrogates such as diagnosis codes, medications, or note concepts must 
be considered. Expert knowledge is necessary to select a variable or a composite variable that meets the high 
PPV and predictor independence requirements15 .  
 
A method for learning from such positive-only data was proposed by Elkan and Noto14. Their method 
predicted the probability of phenotype presence through estimating the probability that a subject is anchor 
positive, motivated by a key observation that the two probabilities differ only by a constant factor, the anchor 
sensitivity. This method requires establishment of the true phenotype status for a random subset of patients 
to obtain a consistent estimate of the anchor sensitivity and phenotype prevalence. Unfortunately, when 
phenotype prevalence is low, the advantage of positive-only design is lost because a large validation 
subsample is needed for accurate estimation of anchor sensitivity. In addition, while this method yields a 
consistent estimate of phenotype prevalence when the predictor distributions for cases and controls are 
completely separable16, the estimated phenotype probability may fall outside of the [0,1] range if the 
predictor distributions overlap, compromising the calibration of the resultant prediction model. Another 
related approach to semi-automated learning of EHR phenotypes assumes random label errors and is most 
suitable for phenotypes that are not rare. This method does not require a validation sample for modeling, but 
does to evaluate method performance17-19. 
 One application for which a positive-only design is advantageous is identifying patients and estimating the 
prevalence of primary aldosteronism (PA) in a clinical practice. Based on epidemiological studies, PA is the 
most common cause of secondary hypertension, thought to affect ~5% of hypertensive patients and up to 
20% of patients with resistant hypertension20-22. PA can be treated effectively by unilateral adrenalectomy or 
targeted medications. Previous methodological work has tried to improve the diagnostic evaluation for PA 
amongst evaluated patients24-26. Unfortunately, PA is not recognized in many affected patients23, so methods 
for EHR phenotyping have the potential to dramatically improve care for these patients.  
 
To enable more efficient and accurate EHR phenotyping in the setting of incomplete clinical training 
phenotypes, we propose a maximum likelihood method to develop a logistic regression prediction model 
using positive-only EHR data that does not require an external validation sample for parameter estimation. 
We have demonstrated, via extensive simulation and application to identify PA patients in our institution’s 
EHR, that this method develops models that accurately identify unlabeled cases and yields consistent 
estimates of phenotype prevalence, anchor sensitivity, and model performance. 
 
  MATERIALS AND METHODS 
 
Positive-only data 
Let 𝑌𝑌denote the binary label for the phenotype (1: case; 0: control), 𝑿𝑿 denote a vector of clinical variables 
that are predictive of 𝑌𝑌, and 𝑆𝑆 denote a binary indicator denoting the anchor variable being positive (1: 
positive; 0: negative). Here (𝑿𝑿,𝑌𝑌, 𝑆𝑆) are considered as random variables with joint distribution 𝑝𝑝(𝑿𝑿,𝑌𝑌, 𝑆𝑆) 
from which EHR patients, including both anchor-positive cases and unlabeled patients, are randomly 
drawn. For a well-chosen anchor variable, its high-PPV property can be stated formally as 
𝑝𝑝(𝑌𝑌 = 1|𝑆𝑆 = 1) = 1. But given its imperfect sensitivity, 𝑌𝑌 can take either value 1 or 0 when 𝑆𝑆 = 0. Let 𝑁𝑁 
denote the total number of patients. Only (𝑿𝑿, 𝑆𝑆)  are observed for all 𝑁𝑁  patients. We use a logistic 
regression working model to relate 𝑌𝑌  and 𝑿𝑿  which is commonly implemented in the EHR setting, 
although our method is applicable for any parametric model that is reasonable for modeling binary 
outcome variables: 
                                                          logit 𝑝𝑝(𝑌𝑌 = 1|𝑿𝑿;𝛽𝛽) = 𝑿𝑿𝑇𝑇𝛽𝛽.                                                               (1) 
Here we allow 𝑿𝑿 to include a vector of 1 so that the intercept parameter is implicitly included in the 
logit function 𝑿𝑿𝑇𝑇𝛽𝛽. For notational simplicity, we use 𝑃𝑃(𝑿𝑿;𝛽𝛽) to denote 𝑝𝑝(𝑌𝑌 = 1|𝑿𝑿;𝛽𝛽). Below, we 
present the likelihood method when anchor sensitivity is a constant.  
 
Phenotyping with an anchor of constant sensitivity 
The constant anchor sensitivity is formalized as conditional independence15, 
𝑝𝑝(𝑆𝑆 = 1|𝑌𝑌 = 1,𝑿𝑿) = 𝑝𝑝(𝑆𝑆 = 1|𝑌𝑌 = 1) ≡ 𝑐𝑐, (2) 
where c is a constant between 0 and 1. For the population defined by 𝑝𝑝(𝑿𝑿,𝑌𝑌, 𝑆𝑆), let 𝐹𝐹(𝑿𝑿) denote the 
cumulative distribution function of 𝑿𝑿, 𝑓𝑓(𝑿𝑿) the corresponding probability density function, and q the 
phenotype prevalence, i.e.  𝑞𝑞 = 𝑝𝑝(𝑌𝑌 = 1) = ∫𝑃𝑃(𝑿𝑿;𝛽𝛽)𝑑𝑑𝐹𝐹(𝑿𝑿).  Let h be the probability of anchor being 
positive, ℎ = 𝑝𝑝(𝑆𝑆 = 1). It is easy to show that anchor sensitivity c equals ℎ/𝑞𝑞 by applying (2). We propose 
to estimate odds ratio parameters β and anchor sensitivity c through maximizing the likelihood function, 
which is the probability of the observed data for the N patients: 
𝐿𝐿(𝛽𝛽, 𝑐𝑐) = �𝑝𝑝(𝑿𝑿𝑖𝑖, 𝑆𝑆𝑖𝑖 = 1)𝑆𝑆𝑖𝑖𝑁𝑁
𝑖𝑖=1
𝑝𝑝(𝑿𝑿𝑖𝑖, 𝑆𝑆𝑖𝑖 = 0)1−𝑆𝑆𝑖𝑖
               ∝�{𝑐𝑐𝑝𝑝(𝑿𝑿𝑖𝑖;𝛽𝛽)}𝑆𝑆𝑖𝑖𝑁𝑁
𝑖𝑖=1
{1 − 𝑐𝑐𝑝𝑝(𝑿𝑿𝑖𝑖;𝛽𝛽)}1−𝑆𝑆𝑖𝑖 
As shown in Appendix A, (𝛽𝛽, 𝑐𝑐) are identifiable with positive-only data. The resultant estimates (?̂?𝛽, ?̂?𝑐) can 
be obtained by maximizing the log likelihood function log𝐿𝐿 (𝛽𝛽, 𝑐𝑐). The large sample variance-covariance 
matrix of these estimates can be obtained from the inverse of the information matrix. We propose two 
methods for estimating phenotype prevalence q. Because q can be expressed as ℎ/𝑐𝑐, it can be estimated as 
𝑞𝑞� = ℎ�/?̂?𝑐, where ℎ� is the maximum likelihood estimate of 𝑝𝑝(𝑆𝑆 = 1) and equal to the sample fraction of those 
with 𝑆𝑆 = 1. Alternatively, it can be estimated as the average of the estimated phenotype probabilities, 
𝑁𝑁−1 ∑ 𝑃𝑃(𝑿𝑿𝑖𝑖, ?̂?𝛽)𝑁𝑁𝑖𝑖=1 .  
 
Model calibration and predictive accuracy measures 
It is important to validate the performance of model (1) for predicting Y with respect to calibration and 
predictive accuracy. But this is not straightforward with positive-only data because Y is unobserved for the 
unlabeled. For calibration, Hosmer-Lemeshow type of goodness-of-fit assessment requires a subsample of 
the unlabeled to have validated Y status. Here we propose an intermediate approach. Because anchor-positive 
cases have definitive phenotype status, we focus on model calibration among the unlabeled. Since the true 
status of Y is unobserved, we propose to compare a non-parametric estimate of case numbers with model-
predicted case numbers in intervals defined by a priori cutoff points for 𝑃𝑃(𝑿𝑿𝑖𝑖, ?̂?𝛽). Within interval 𝑎𝑎 <
𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏, where 𝑎𝑎 and 𝑏𝑏 are two positive numbers in the range of (0,1), we can show that 
𝑝𝑝�𝑌𝑌 = 1|𝑎𝑎 < 𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏, 𝑆𝑆 = 0� = 𝑝𝑝�𝑎𝑎 < 𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏|𝑌𝑌 = 1, 𝑆𝑆 = 0�𝑝𝑝{𝑌𝑌 = 1,𝑆𝑆 = 0}𝑝𝑝�𝑎𝑎 < 𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏, 𝑆𝑆 = 0�                                       = (𝑞𝑞 − ℎ)𝑝𝑝�𝑎𝑎 < 𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏, 𝑆𝑆 = 1�
ℎ𝑝𝑝�𝑎𝑎 < 𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏, 𝑆𝑆 = 0� .                                                       
A nonparametric estimate of 𝑝𝑝�𝑌𝑌 = 1|𝑎𝑎 < 𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏, 𝑆𝑆 = 0� can then be obtained as 
?̂?𝑝𝑛𝑛�𝑌𝑌 = 1|𝑎𝑎 < 𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏, 𝑆𝑆 = 0� = (𝑞𝑞∗ − 𝑁𝑁−1 ∑ 𝑆𝑆𝑖𝑖𝑁𝑁𝑖𝑖=1 )𝑁𝑁−1 ∑ 𝐼𝐼𝑁𝑁𝑖𝑖=1 �𝑎𝑎 < 𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏, 𝑆𝑆𝑖𝑖 = 1�(𝑁𝑁−1 ∑ 𝑆𝑆𝑖𝑖)𝑁𝑁𝑖𝑖=1 𝑁𝑁−1 ∑ 𝐼𝐼𝑁𝑁𝑖𝑖=1 �𝑎𝑎 < 𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏, 𝑆𝑆𝑖𝑖 = 0� . 
Here 𝑞𝑞∗ can be the MLE derived above, 𝑞𝑞�, which makes the estimate ?̂?𝑝𝑛𝑛 not completely “nonparametric”. 
But it can also be an educated guess by clinicians or from other investigations, which is often available for 
EHRs. Let ?̂?𝑝𝑚𝑚�𝑌𝑌 = 1|𝑎𝑎 < 𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏, 𝑆𝑆 = 0� denote the model-based estimate of 𝑝𝑝�𝑌𝑌 = 1|𝑎𝑎 <
𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏, 𝑆𝑆 = 0�. We have  
?̂?𝑝𝑚𝑚�𝑌𝑌 = 1|𝑎𝑎 < 𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏, 𝑆𝑆 = 0� = ∑ (1 − ?̂?𝑐)𝑃𝑃�𝑿𝑿𝒊𝒊, ?̂?𝛽�𝐼𝐼�𝑎𝑎 < 𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏�𝑁𝑁𝑖𝑖=1∑ {1 − ?̂?𝑐𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽�}𝐼𝐼�𝑎𝑎 < 𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏�𝑁𝑁𝑖𝑖=1 . 
We propose to compare ?̂?𝑝𝑛𝑛 and ?̂?𝑝𝑚𝑚 for assessing model calibration, where similar values of ?̂?𝑝𝑛𝑛�𝑌𝑌 = 1|𝑎𝑎 <
𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏, 𝑆𝑆 = 0� and ?̂?𝑝𝑚𝑚�𝑌𝑌 = 1|𝑎𝑎 < 𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 𝑏𝑏, 𝑆𝑆 = 0� indicate good calibration. 
For a well-calibrated model 𝑃𝑃(𝑿𝑿;𝛽𝛽) as indicated by our method above, we study the predictive accuracy of 
the model among the unlabeled. To evaluate the accuracy of model (1) for classification, we consider 
statistical measures including true positive rate (𝑇𝑇𝑃𝑃𝑇𝑇𝑣𝑣), false positive rate (𝐹𝐹𝑃𝑃𝑇𝑇𝑣𝑣), positive predictive 
value (𝑃𝑃𝑃𝑃𝑃𝑃𝑣𝑣), negative predictive value (𝑁𝑁𝑃𝑃𝑃𝑃𝑣𝑣) at a decision threshold v and area under the 𝑇𝑇𝑅𝑅𝑅𝑅 curve (𝐴𝐴𝐴𝐴𝑅𝑅). Given that anchor-positive patients are classified as cases by definition, we propose to assess model 
performance only in the unlabeled patients. Interestingly, we found that these measures can all be estimated 
using positive-only data without requiring that model (1) reflects the true relationship between Y and X, a 
feature that is particularly attractive for EHR data.  TPRv is defined as 
𝑇𝑇𝑃𝑃𝑇𝑇𝑣𝑣 = 𝑝𝑝{𝑃𝑃(𝑿𝑿;𝛽𝛽) > 𝑣𝑣|𝑌𝑌 = 1, 𝑆𝑆 = 0}. 
The constant anchor sensitivity requirement warrants that S and X are independent given 𝑌𝑌 = 1. Therefore, 
𝑇𝑇𝑃𝑃𝑇𝑇𝑣𝑣 for the unlabeled is equal to that for anchor-positive cases, 𝑇𝑇𝑃𝑃𝑇𝑇𝑣𝑣 = 𝑝𝑝{𝑃𝑃(𝑿𝑿;𝛽𝛽) > 𝑣𝑣|𝑌𝑌 = 1, 𝑆𝑆 = 1} . 
This implies that 𝑇𝑇𝑃𝑃𝑇𝑇𝑣𝑣 for the unlabeled can be estimated using anchor-positive cases as 
𝑇𝑇𝑃𝑃𝑇𝑇𝑣𝑣� = ?̂?𝑝{𝑃𝑃(𝑿𝑿;𝛽𝛽) > 𝑣𝑣|𝑆𝑆 = 1} = 𝑁𝑁−1 ∑ 𝐼𝐼{𝑃𝑃�𝑿𝑿𝒊𝒊; ?̂?𝛽� > 𝑣𝑣, 𝑆𝑆𝑖𝑖 = 1}𝑁𝑁𝑖𝑖=1 ℎ� . 
The 𝐹𝐹𝑃𝑃𝑇𝑇𝑣𝑣 is defined and further-rewritten as  
𝐹𝐹𝑃𝑃𝑇𝑇𝑣𝑣 = 𝑝𝑝{𝑃𝑃(𝑿𝑿;𝛽𝛽) > 𝑣𝑣|𝑌𝑌 = 0, 𝑆𝑆 = 0} = 𝑝𝑝{𝑃𝑃(𝑿𝑿;𝛽𝛽)>𝑣𝑣,𝑆𝑆=0}−𝑝𝑝{𝑃𝑃(𝑿𝑿;𝛽𝛽)>𝑣𝑣|𝑆𝑆=1}𝑝𝑝(𝑌𝑌=1,𝑆𝑆=0)𝑝𝑝(𝑌𝑌=0) . 
Therefore, it can be estimated similarly as 
𝐹𝐹𝑃𝑃𝑇𝑇𝑣𝑣� = 𝑁𝑁−1 ∑ 𝐼𝐼�𝑃𝑃�𝑿𝑿𝒊𝒊; ?̂?𝛽� > 𝑣𝑣, 𝑆𝑆𝑖𝑖 = 0�𝑁𝑁𝑖𝑖=1 (1 − 𝑞𝑞�) − (𝑞𝑞� − ℎ�)𝑁𝑁−1 ∑ 𝐼𝐼�𝑃𝑃�𝑿𝑿𝒊𝒊; ?̂?𝛽� > 𝑣𝑣, 𝑆𝑆𝑖𝑖 = 1�𝑁𝑁𝑖𝑖=1ℎ�(1 − 𝑞𝑞�) , 
Where ℎ� = 𝑁𝑁−1 ∑ 𝑆𝑆𝑖𝑖𝑁𝑁𝑖𝑖=1 ,𝑞𝑞� = 𝑁𝑁−1 ∑ 𝑃𝑃(𝑿𝑿𝑖𝑖,𝛽𝛽�)𝑁𝑁𝑖𝑖=1 . 
Similar estimates of 𝑃𝑃𝑃𝑃𝑃𝑃𝑣𝑣, 𝑁𝑁𝑃𝑃𝑃𝑃𝑣𝑣, and 𝐴𝐴𝐴𝐴𝑅𝑅 are provided in Appendix C. We obtain standard errors of the 
estimated predictive accuracy measures based on 1000 bootstrap iterations. 
 Simulation studies 
We carried out extensive simulation studies to evaluate the performance of our method (See Supplementary 
Material, Appendix D). 
 
Clinical data  
Demographics, laboratory results, encounter metadata, diagnosis codes, and unstructured clinical text were 
retrospectively queried and extracted from between January 1, 1997 and July 1, 2017 from the University 
of Pennsylvania Health System (UPHS) clinical data repository and PennChart EPIC Clarity reporting 
database. Individual laboratory test results and vital signs were selected that were temporally closest to, and 
no more than 14 days from, the date of the blood aldosterone testing. Diagnosis codes for primary 
aldosteronism or other hyperaldosteronism were counted. To describe patients’ time in our healthcare 
system, we calculated pairwise time intervals between each patient’s first encounter, last encounter, initial 
PA screening laboratory testing, and PA evaluative adrenal vein sampling (AVS) procedure. Notes were 
queried using a series of regular expressions (Table S1) and counts were summed per patient. Variables 
with highly positively skewed distributions were log-transformed, and all continuous variables were 
standardized.  Code and full data dictionaries are available in http://bitbucket.com/hermanlab/PhIAP. 
Analyses were restricted to the subset of patients with complete data on included variables, simplistically 
assuming that the missingness (Table S2) was completely at random. PA anchor variable was implemented 
initially leveraging an existing PA research database curated through 201527 (Anchor 1) and later 
supplemented by adding positive cases that had laboratory results for an AVS procedure (Anchor 2). 
Patient charts for all patients identified by the two final positive-only models with ?̂?𝑝(𝑌𝑌 = 1|𝑿𝑿) ≥ 0.2, 2+ 
diagnosis codes, or strict laboratory criteria (blood aldosterone ≥ 15 ng/Dl, renin activity ≤ 0.5 ng/mL/hr, 
aldosterone:renin ≥ 30) were reviewed by clinician I.A. and unclear cases were further reviewed by D.S.H. 
This study was reviewed and approved by the University of Pennsylvania IRB. 
 RESULTS 
Simulation studies   
Our proposed method generated consistent and efficient estimates for β, c, q, and predictive accuracy 
measures across a wide range of phenotype prevalence (Table S3-S6) and anchor sensitivity (Tables S7, 
S8). Model lack-of-fit, deviation of the fitted model from the data generating model, could impact the 
parameter estimation and predictive accuracy. Simulation showed that the parameter estimators were 
relatively robust to minor model misspecifications, but did deviate with major model misspecifications 
(Tables S4). To address this, we showed that our proposed method of assessing calibration can detect such 
deviations (Table S5). In addition, since anchor sensitivity is not always fixed, we showed that in the setting 
of known, multi-level anchor sensitivity, stratified modeling yielded better performance (Table S10-S12). 
 
Application to identify patients with diagnosed primary aldosteronism in EHR data 
To identify PA patients in our healthcare system, we extracted EHR data for 6,319 patients who had an 
order for a PA screening laboratory test, blood aldosterone concentration, between January 01, 1997 and 
July 01, 2017. We first selected as training cases patients with definitive PA based on a documented history 
of an AVS procedure, for PA evaluation, or unilateral adrenalectomy, for PA management. We considered 
two derivations of this composite anchor phenotype, which we will refer to as anchor 1 and anchor 2. 
Anchor 1 labeled 101 (2.8%) patients as PA cases and the anchor 2 labeled an additional 34 patients, 
increasing the set of PA patients to a total of 135 (3.8%). Next, to identify additional PA patients among the 
unlabeled patients, we considered two rule-based algorithms: presence of 2 or more diagnosis codes or the 
presence of PA laboratory testing results that meet conservative diagnostic criteria. Based on chart review, 
these heuristics demonstrated excellent PPVs of 85% and 90%, respectively. However, they appeared to 
have only modest sensitivity, because they failed to flag all anchor-positive patients. 
To identify further PA patients, we trained models using our novel method EHR phenotyping with 
internally assessable performance (PhIAP) using anchor-positive and unlabeled patients. We first separately 
developed preliminary logistic regression models trained using each of the anchor phenotypes. We selected 
and engineered potential predictors based on clinical expertise and univariate logistic regression models for 
predicting anchor positivity, ultimately including four demographic variables, six variables for laboratory 
results, eight variables for summarizing encounter metadata, two variables aggregating diagnosis codes, 
and six variables extracted from unstructured clinical text (Table S2). We applied our proposed method, 
starting with a baseline model that included only variables available at the time of PA diagnostic laboratory 
screening, including demographics, blood pressure, and time in health system prior to PA screening (Tables 
S13, S14). Then we serially added further sets of variables until all candidate predictors were included. 
Finally, we performed backward stepwise variable selection until all included variables had p-values less than 
0.1. Upon determination of a final subset of predictors, we fitted the final prediction model among the 3579 
patients who had complete data for these included variables (Tables S15, S16). This final population had 
demographics and laboratory results comparable to that of the full cohort (Table S17). 
 
The baseline model using anchor 1 estimated the phenotype prevalence 𝑞𝑞� as 0.30 (estimated asymptotic 
standard error (SE): 0.05) and anchor sensitivity ?̂?𝑐  as 0.10 (SE: 0.02). This 𝑞𝑞�  was much higher than 
expected. As the subsequent four sets of variables were sequentially added, ?̂?𝑐 became 0.58, 0.64, 0.49 and 
0.45, respectively. The corresponding prevalence estimates for  𝑞𝑞� were 0.05, 0.05, 0.07 and 0.08 (Table S13). 
Results were similar when anchor 2 was used to label cases, except that the estimated anchor sensitivities 
were higher (Table S14). For both anchors, ?̂?𝑐  and 𝑞𝑞�  estimates from the baseline model appeared very 
different from the subsequent, richer models. To probe the baseline model, we applied our proposed method 
for evaluating calibration (Table S18). The nonparametrically-estimated and model-predicted case numbers 
in the pre-defined intervals of predicted probabilities were quite different, suggesting poor calibration. For 
example, the nonparametrically-estimated case number was 69 in interval 0.7 < 𝑃𝑃�𝑿𝑿𝑖𝑖, ?̂?𝛽� < 0.8, compared 
to model-predicted case number of 43.  
 
For the final model using anchor 1, 𝑞𝑞� was estimated to be 0.08 (SE: 0.01) and ?̂?𝑐 was estimated to be 0.37 
(SE: 0.05), which predicted that there were 171 unlabeled PA patients. With Anchor 2,  ?̂?𝑐 increased to 0.55 
(SE: 0.04), which was expected because Anchor 2 labeled more PA patients. The PA prevalence was 
estimated to be 0.07 (SE: 0.01). For both anchors, the final prediction model appeared well calibrated, with 
similar nonparametrically-estimated and model-predicted case numbers in each fixed interval of predicted 
probabilities (Table 1). The final prediction model also appeared to have high discriminatory power. The 
estimated probabilities of PA presence, ?̂?𝑝(𝑌𝑌 = 1|𝑿𝑿) showed good separation between groups, with anchor-
positive cases mostly having high predicted probabilities (Figure 1). 
 
Table 1. Model-predicted vs. nonparametrically-estimated case numbers in pre-defined intervals of predicted 
probabilities. The two estimated numbers were compared in each interval of predicted probabilities to 
inform model calibration. 
 Anchor 1  Anchor 2 
Interval Model-
predicted 
Nonparametrically-
estimated 
 Model-
predicted 
Nonparametrically-
estimated 
0.0_0.1 11 12  7 7 
0.1_0.2 6 8  4 4 
0.2_0.3 6 3  3 6 
0.3_0.4 5 7  3 1 
0.4_0.5 6 7  3 5 
0.5_0.6 9 8  5 3 
0.6_0.7 5 0  3 3 
0.7_0.8 10 8  5 5 
0.8_0.9 13 10  7 6 
0.9_1.0 98 99  82 76 
 
We evaluated predictive accuracy of the final selected model using 10-fold cross validation and reported 
empirical standard errors (ESE) based on 1000 bootstrap iterations. For both anchors, the model achieved 
an averaged AUC of 0.99 (ESE: 0.005). With anchor 1, the respective estimates of PPV and TPR were 0.65 
(ESE: 0.10) and 0.89 (ESE: 0.03) at decision threshold 0.2, and 0.83 (ESE: 0.05) and 0.79 (ESE: 0.06) at 
threshold 0.5. With anchor 2, these estimates were 0.63 (ESE: 0.11) and 0.91 (ESE: 0.04) at threshold 0.2 
and 0.82 (ESE: 0.08) and 0.82 (ESE: 0.06) at threshold 0.5 (Table 2). Chart review of the patients the 
models predicted to be diagnosed with PA revealed similar PPVs of 74% and 80% (anchor 1) and 74% and 
77% (anchor 2) at decision thresholds of 0.2 and 0.5, respectively. Notably, among PA patients not flagged 
by either of the originally evaluated rule-based algorithms, these models identified 7 additional PA 
patients.  
 
Table 2. Estimated predictive accuracy measures (Empirical Standard Error) of resultant classifiers with 
each of the two anchors. The AUC was estimated to be 0.993 (ESE: 0.005) for both anchors. 
 
 Anchor1  Anchor 2 
Cutoff 0.2 0.3 0.4 0.5  0.2 0.3 0.4 0.5 
PPV 0.653 
(0.101) 
0.736 
(0.079) 
0.791 
(0.062) 
0.833 
(0.047) 
 0.629 
(0.112) 
0.709 
(0.104) 
0.765 
(0.093) 
0.822 
(0.080) 
TPR 0.894 
(0.031) 
0.865 
(0.039) 
0.837 
(0.047) 
0.786 
(0.056) 
 0.906 
(0.035) 
0.876 
(0.044) 
0.847 
(0.053) 
0.816 
(0.062) 
NPV 
 
0.994 
(0.001) 
0.993 
(0.002) 
0.992 
(0.002) 
0.989 
(0.002) 
 0.997 
(0.001) 
0.996 
(0.001) 
0.995 
(0.002) 
0.994 
(0.002) 
FPR 0.024 
(0.005) 
0.016 
(0.004) 
0.011 
(0.002) 
0.008 
(0.002) 
 0.017 
(0.005) 
0.012 
(0.003) 
0.008 
(0.002) 
0.006 
(0.002) 
  
 
DISCUSSION 
A key step to comprehensive and accurate EHR phenotyping is the development of accurate algorithms that 
efficiently leverage clinical expertise and available data. Currently, most existing methods require a 
complete set of expert-annotated cases and controls to train phenotyping algorithms or incorrectly treat 
unlabeled patients as definitive controls. Our proposed method builds accurate model classifiers based upon 
a random sample of positive cases and a large number of unlabeled patients. To identify a random sample 
of cases, the method can leverage domain expertise summarized in the form of an anchor variable, with 
modest upfront effort from clinical experts15. Compared to standard strategies, this method dramatically 
decreases the need for labor-intensive chart annotation and prospective phenotyping.  
 
The model performance relies upon the independence of anchor sensitivity and model predictors, which 
necessitates meticulous selection of the anchor based on clinical expertise.  If unclear, the appropriateness 
of an anchor could be supported by explicitly validating the estimated phenotype prevalence, model 
sensitivity, or the conditional independence assumption. We refer readers to Halpern’s work15,28 for 
methods to support defining potential anchors. In this work, we also extended the current implementation of 
anchor variables to allow anchor sensitivity to vary across a fixed number of discrete strata that are defined 
by patient EHR data (Appendix B).  Recent work has considered phenotyping methods that take advantage 
of both noisy labels with random error and anchor variable framework18. Our method can be extended in 
this regard.  
 
We proposed novel statistical methods for assessing calibration and predictive accuracy of the developed 
prediction model. A model must be well-calibrated for predictive accuracy measures to meaningfully 
inform model performance. Classically, validating models requires annotated controls or labels for a 
random sample of patients. To assess calibration, we developed a novel approach that took advantage of the 
defining characteristics of an anchor variable to use only the observed data for anchor-labeled cases and the 
unlabeled patients. In the analysis of Penn EHR data and our simulation studies, we showed that poor 
calibration of the model or breaking the conditional independence assumption can lead to severely biased 
estimates of anchor sensitivity and phenotype prevalence. Fortunately, our proposed calibration method can 
help detect poor calibration, and the estimates appeared to be largely consistent as long as our method 
indicates good calibration even in the setting of minor model misspecification. This is very important, 
because a good estimate of anchor sensitivity and its confidence interval can reveal the extent of undetected 
cases among the unlabeled patients and identify individual unlabeled patients. It is challenging to 
confidently scale previous methods for positive-only model learning to large numbers of phenotypes, 
because of the delicacy of the conditional independence assumption and the necessity for external 
validation. However, PhIAP’s internal assessment of model performance should enable it to scale robustly. 
 
Another attractive feature of this method is transferability to other practices. The anchor concept may itself 
be more easily transferred rather than the full model18. At secondary sites, chart review need only be 
performed to confirm that the anchor has very high PPV for the single phenotype of interest, which is 
considerably less burdensome validation of a classically fit or transferred model. Unlike previous 
implementations of such positive-only model development, because of the internal assessment of model 
performance, if a model can be fit locally with good performance parameters, then there is no absolute need 
for additional chart review. 
 
In this work, we applied our method to develop models to identify patients with PA. In selecting as anchor 
variables the PA subtyping diagnostic procedure and surgical treatment, we targeted patients with more 
severe and actionable disease rather than all PA patients. Thus, based on the conditional independence 
assumption, our models suggest that amongst screened patients the prevalence of patients with similarly 
severe PA that are potentially candidates for surgery is approximately 7%. In contrast, while the method 
should construct models to rule-out phenotypes with a high negative predictive value, our selection of 
anchor variable is not ideal for this purpose because many patients with PA are not surgical candidates and 
not all have severe enough disease that they come to clinical attention. In addition, there are likely 
socioeconomic factors, care variability, and other logistic factors that are associated with anchor positivity. 
Properly adjusting for these effects will require more complex anchors and models. One natural extension 
of this strategy, for similarly complex phenotypes, would be derivation of a separate anchor variable and 
separate model for definitively negative PA controls. 
 
Our models were estimated to have PPVs comparable to that of the originally evaluated rule-based 
algorithms and also identified several patients not flagged by these heuristics. But, as this was a proof-of-
method concept, we focused on specific predictors selected by domain experts, did not exhaustively explore 
feature selection and engineering, and excluded patients with incomplete data from analysis. We would 
expect considerable further gains from more extensive modeling, and we plan to consider suitable missing 
data approaches to allow inclusion of all patients. In addition, our current method is suitable for developing 
phenotyping models when the number of potential predictors is far less than the number of records. It is of 
interest to explore additional predictors across high dimensional EHR data, which we expected would lead 
to models with improved accuracy and more precise estimates of anchor sensitivity. We plan to extend our 
current method to facilitate variable selection in building the prediction model. 
 
CONCLUSION 
The incompleteness and asymmetry of EHR data limits its use for clinical decision support and research. 
We have developed a novel likelihood-based method that uses anchor-positive and unlabeled patients to 
simultaneously enable accurate model development, identification of unlabeled cases, and internal 
assessment of model performance. We expect this method will facilitate model development and 
transferability for a wide variety of EHR clinical decision support and research applications. 
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FIGURE LEGENDS 
 
Figure 1. Histogram of estimated probabilities of PA, ?̂?𝑝(𝑌𝑌 = 1|𝑿𝑿) for anchor 1 (A) and anchor 2 (B).  The 
left panels display the probability histogram with the range of y-axis being 0-100%. The right panels display 
the zoomed-in probability histogram with y-axis limited to 0-6%. Anchor-positive (blue) and unlabeled 
patients (red) indicated.  
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Appendix A: Proof of Parameter Identifiability
Note that we have a random sample of (X, S)’s, hence the observations Xi’s form a random sample of f(X).
Thus, obviously, f(X) is identifiable. Likewise, the observations Si’s form a random sample of the pmf of S,
hence h is obviously identifiable. As derived above, the joint pdf of (X, S) is
f(X)
{
hP (X;β)∫
P (X;β)f(X)dX
}I(S=1){
1− hP (X;β)∫
P (X;β)f(X)dX
}I(S=0)
with unknown parameters h,β, f(X). Note that the observed (X, S) is a random sample from the underlying
population, thus f(X) and c are obviously identifiable. Assume that β is not identifiable. Then there exists
β∗ so that p(X, S;β) = p(X, S;β∗) for all (X, S) pairs, which can be formalized as:{
hP (X;β)∫
P (X;β)f(X)dX
}I(S=1){
1− hP (X;β)∫
P (X;β)f(X)dX
}I(S=0)
=
{
hP (X;β∗)∫
P (X;β∗)f(X)dX
}I(S=1){
1− hP (X;β
∗)∫
P (X;β∗)f(X)dX
}I(S=0)
.
Letting S = 1, this equation reduces to
hP (X;β)∫
P (X;β)f(X)dX =
hP (X;β∗)∫
P (X;β∗)f(X)dX ,
or equivalently
P (X;β∗)
P (X;β) =
∫
P (X;β∗)f(X)dX∫
P (X;β)f(X)dX . (1)
Note that the right hand side of (1) is a positive constant, hence the left hand side is also a constant. When
the covariates Xj →∞ if βj > 0 and Xj → −∞ if βj ≤ 0, regardless what the intercept term is, P (X;β)→ 1
and P (X;β∗) converges to either 1 or 0. Thus, the left hand side goes to either 1 or 0. Because the right
hand side is positive, hence we further conclude that the left hand side goes to 1. Because it has to be a
constant, this implies that the left hand side is always 1, i.e. P (X;β∗) = P (X;β) at all X. Thus β = β∗,
i.e. β is identifiable. Once β, h, f(X) are indentifiable, the disease prevalence q =
∫
P (X;β)f(X)dX is
identifiable by definition.
Appendix B: Phenotyping with an anchor of varying sensitivity
Suppose that the population can be divided into K strata of size Nk, where the kth stratum is indicated by
zk, k = 1, ...,K. Within each substratum, the anchor has a constant sensitivity. For notational convenience,
Z is included as a component of predictors X. The problem is then formalized as stratified conditional
independence,
p(S = 1|Y = 1,X) = p(S = 1|Y = 1, Z = zk) = ck, k = 1, ...,K.
1
Model (??) remains the working model for prediction, where Z, if not predictive, has a log odds ratio equal
to zero. The probability of observed data of an anchor-positive case and an unlabeled patient in each stratum
is generalized as below to reflect variation in anchor sensitivity,
p(X, S = 1) = ckp(Y = 1|X)p(X),
p(X, S = 0) = {1− ckp(Y = 1|X)}p(X).
The likelihood function becomes the probability of observed data across all K strata,
l(β, {ck}) ∝
N∑
i=1
K∑
k=1
I(Zi = zk)[Si log{ckP (Xi;β)}+ (1− Si) log{1− ckP (Xi;β)}]
Parameter identifiability can be shown similarly as in the situation of constant anchor sensitivity. The
MLE of β and {ck, k = 1, ...,K} can be obtained by maximizing the log likelihood function l(β, {ck}).
Let qk ≡ p(Y = 1|zk) denote the phenotype prevalence in the kth stratum. Then qk can be estimated as
hˆk/cˆk, where hˆk is the estimated anchor prevalence in the kth stratum, pˆ(S = 1|Z = zk) =
∑N
i=1 I(Zi =
zk, Si = 1)/Nk. The overall phenotype prevalence q can then be estimated as a weighted summation of qk’s,
qˆ =
∑K
k=1Nkqˆk/N .
Appendix C: Predictive Accuracy Measures
The accuracy measures are defined and further re-written as:
TPRv = p{P (X;β) > v|Y = 1, S = 0}
= p{P (X;β) > v|Y = 1, S = 1}
= p{P (X;β) > v|S = 1}
FPRv = p{P (X;β) > v|Y = 0, S = 0}
= p{P (X;β) > v, S = 0} − p{P (X;β) > v, S = 0, Y = 1}
p(Y = 0, S = 0)
= p{P (X;β) > v, S = 0} − p{P (X;β) > v|Y = 1, S = 0}p{Y = 1, S = 0}
p(Y = 0)
= p{P (X;β) > v, S = 0} − p{P (X;β) > v|S = 1}[p{Y = 1} − p{Y = 1, S = 1}]
p(Y = 0)
PPVv = p{Y = 1|P (X;β) > v, S = 0}
= p{P (X;β) > v|Y = 1, S = 0}p{Y = 1, S = 0}
p{P (X;β) > v, S = 0}
= p{P (X;β) > v|S = 1}[p{Y = 1} − p{Y = 1, S = 1}]
p{P (X;β) > v, S = 0}
NPVv = p{Y = 0|P (X;β) < v, S = 0}
= p{P (X;β) < v, S = 0} − p{P (X;β) < v, S = 0, Y = 1}
p{P (X;β) < v, S = 0}
= p{P (X;β) < v, S = 0} − p{P (X;β) < v|S = 1}pY = 1, S = 0
p{P (X;β) < v, S = 0}
AUC =
∫
TPRvdFPRv
Thus they can be estimated as:
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T̂PRv =
N−1
∑N
i=1 I{P (Xi; β̂) > v, Si = 1}
N−1
∑N
i=1 I(Si = 1)
F̂PRv =
N−1
∑N
i=1 I{P (Xi; β̂) > v, Si = 0}
1−N−1∑Ni=1 P (Xi; β̂)
− [N
−1∑N
i=1 I{P (Xi; β̂) > v, Si = 1}]{N−1
∑N
i=1 P (Xi; β̂)−N−1
∑N
i=1 I(Si = 1)}
{N−1∑Ni=1 I(Si = 1)}{1−N−1∑Ni=1 P (Xi; β̂)}
P̂PVv =
[N−1
∑N
i=1 I{P (Xi; β̂) > v, Si = 1}]{N−1
∑N
i=1 P (Xi; β̂)−N−1
∑N
i=1 I(Si = 1)}
{N−1∑Ni=1 I(Si =)}[N−1∑Ni=1 I{P (Xi; β̂) > v, Si = 0}]
N̂PVv = 1− [N
−1∑N
i=1 I{P (Xi; β̂) < v, Si = 1}]{N−1
∑N
i=1 P (Xi; β̂)−N−1
∑N
i=1 I(Si = 1)}
{N−1∑Ni=1 I(Si =)}[N−1∑Ni=1 I{P (Xi; β̂) < v, Si = 0}]
ÂUC =
∫
T̂PRvdF̂PRv.
Appendix D: Simulation Studies
We carried out extensive simulation studies to evaluate the performance of our method mainly in three
aspects: (i) to demonstrate statistical consistency of our proposed estimators for c, q, and predictive accuracy
measures; (ii) to evaluate the impact of model mis-specification on estimation of c and q and predictive
accuracy; and (iii) to assess model performance when the anchor sensitivity is not fixed.
Simulation study design We generated the binary outcome variable Y from the following logistic regression
model:
logit p(Y = 1|X;β) = β0 +
9∑
k=1
βkXk (2)
with (X1, X2, X3), (X4, X5, X6) and (X7, X8, X9) representing groups of weak, moderate, and strong
predictors, respectively. The three corresponding groups of parameter values were set as (β1, β2, β3) =
(0.2, 0.4, 0.6), (β4, β5, β6) = (−1.0,−1.4, 1.8), and (β7, β8, β9) = (−2.0, 2.4, 2.8), respectively. We considered
four different phenotype prevalences, 5%, 10%, 15% and 20%, by setting the intercept parameter β0 at values
-2.5, 1.0, 3.3 and 5.4, respectively. The 9 predictors were independently distributed, with X1, X4 and X7
generated from normal distribution N(5, 10), X2, X5 and X8 from Bernoulli distribution with success rate
0.5, and X3, X6 and X9 from logit transformed standard uniform distribution. The anchor sensitivity
c = p(S = 1|Y = 1) was fixed at 0.5, so that h takes four different values, 0.025, 0.05, 0.075 and 0.1,
corresponding to the four different values of phenotype prevalence. In each Monte Carlo experiment, we first
generated X for a target population with covariates as described above, then phenotype Y according to
model (2). For each case (Y = 1), the anchor variable S was generated according to a Bernoulli distribution
with parameter c. For the controls (Y = 0), we set S = 0. Then we drew a random sample of size 10, 000
as the training set, and pulled a disjoint testing set of size 5, 000. For each parameter combination, we
iterated the simulation 1, 000 times. Below we focus our discussion on the results at phenotype prevalence
10%. Results for the other three prevalence values 5%, 15% and 20% were similar and were included in the
supplementary materials.
Simulation results When the data-generating model (2) above was fitted to each simulated dataset, the
averaged parameter estimates (βˆ) appeared very close to the true values ( Table S3). The negligibly small bias
(< 4%) indicated statistical consistency of the proposed MLE estimator. The averaged estimated asymptotic
standard errors (“SE”) and the empirical standard errors (“ESE”) were very close with difference < 6%.
The anchor sensitivity c was estimated to be 0.500 (SE: 0.021; 95% CI: 0.459, 0.541), and consequently
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the phenotype prevalence q was estimated to be 0.100 (SE: 0.004; 95% CI: 0.094, 0.106) (Table S4). The
fitted model was well calibrated as the nonparametrically-estimated and model-predicted cases numbers
were comparable ( Table S5). PPV and TPR were estimated to be 0.798 (ESE: 0.056) and 0.852 (ESE:
0.024) respectively with decision threshold set at 0.5, which were very close to the “true values” (when Y is
truely observed for everyone) of PPV and TPR at 0.797 (ESE: 0.029) and 0.852 (ESE: 0.024). The AUC
was estimated as 0.994 (ESE: 0.003), comparable to the “true value” of 0.993 (ESE: 0.001). The estimated
predictive accuracy measures and their “true values” at other decision thresholds are summarized in Table S6.
To investigate the variation in model performance with respect to anchor sensitivity c, we considered two
values for c, 0.5 and 0.2. With 10,000 observations in the training set and phenotype prevalence 10%, taking
0.5 as the decision threshold, the anchor variable helped identify 536 cases when c equaled 0.5 and 797 cases
when c equaled 0.2. The estimates of c and q appeared to be consistent in both cases, although those at
c = 0.2 had wider confidence intervals as expected (Table S4). The predictive accuracy of the fitted models
were also comparable (Table S7). The OR estimates βˆ appeared somewhat biased when c = 0.2. However,
the bias largely disappeared when the size of the training set was increased to 20, 000 (Table S8). The model
calibration also improved with the increased training set size (Table S9). The number of anchor-positive
cases appeared to be most relevant in such bias reduction and calibration improvement in further unreported
investigations.
We further explored the impact of model mis-specification on the performance of our proposed method. The
models for analyzing EHR data are best considered as working models, and it is difficult to envision an
underlying true model. By allowing deviation of the fitted model from the data generating model, we aimed to
evaluate whether the resultant lack of fit is detectable by our method of assessing calibration and to evaluate
whether our method of assessing calibration can inform unbiasedness of parameter estimation. Omission of
weak predictors (X1, X2, X3) from model (2) had minor impact on model calibration and accuracy. However,
omission of the strong (X7, X8, X9) predictors led to poor model calibration. The nonparametrically-estimated
case numbers were very different from the model-predicted case numbers as shown in Table S5. Parameter
estimation was sensitive to model misspecification as expected. The estimate of anchor sensitivity c was 0.496
(SE: 0.023; 95% CI: 0.451, 0.541) and 0.358 (SE: 0.110; 95% CI: 0.142, 0.574) under the two mis-specified
models respectively. The phenotype prevalence q was correspondingly estimated as 0.101 (SE: 0.004; 95% CI:
0.093, 0.109) and 0.221 (SE: 0.036; 95% CI: 0.150, 0.292) respectively, where the bias in the latter estimate
appeared to be biased as the 95% CI did not include true value 0.100 (Table S4). To summarize, the impact
of model-misspecification on the performance of our method can be large, but can be detected through model
calibration.
To assess the model performance when the anchor sensitivity varies, we simulated a new population following
the same steps as above, except that it consisted of two strata indicated by a binary variable Z that takes value
0 or 1 with probability p(Z = 1) = 0.5. Conditional on the phenotype the anchor variable was independent of
all predictors within each strata, with c1 = p(S = 1|Y = 1, Z1) = 0.2, and c2 = p(S = 1|Y = 1, Z2) = 0.8.
Applying the proposed method that takes the stratified conditional independence into account, the parameter
estimates, βˆ, cˆ1, cˆ2, qˆ, appeared consistent (Table S10). The anchor sensitivity c1 was estimated to be
0.201 (SE: 0.025; 95% CI: 0.151, 0.251), c2 was estimated to be 0.800 (SE: 0.022; 95% CI: 0.757, 0.843),
and consequently the phenotype prevalence q was estimated to be 0.100 (SE: 0.004; 95% CI: 0.091, 0.109).
The fitted model was well calibrated and demonstrated good predictive accuracy (Table S11, S12). On the
other hand, if the variation in anchor sensitivity failed to be recognized, the fitted model can lead to biased
parameter estimates (Table S10), and notable decrease in predictive accuracy. The “true values” of TPR
dropped from 0.845 to 0.516 at decision threshold 0.5, and AUC dropped from 0.993 to 0.976, although not
much decrease was observed on PPV . (Table S12). To conclude, it is crucial to recognize the stratification,
especially when the anchor sensitivities varies a lot.
Appendix E: Supplementary Tables
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Table S1. Notes query table
Key words Expression
hyperaldo hyperaldo
hyperaldo_spec (?<!not\s)(?<!secondary\s)(?<!ruled out\s)(?<!ruling out\s)hyperaldo
primary_hyperaldo_spec (?<!not\s)(?<!secondary\s)(?<!ruled out\s)(?<!ruling out\s)primary hyperaldo
primary_aldo primary aldo
primary_aldo_spec (?<!not\s)(?<!rule out\s)(?<!n't suggest\s)primary aldo
avs adrenal vein sampl|\bavs\b
bah bilateral adrenal hyperplasia|\bbah\b
bah_spec (?<!not\s)bilateral adrenal hyperplasia|(?<!not\s)\bbah\b
aldo_producing_adenoma aldo\w{0,7}([-\s]producing)?([-\s]ade)?noma
aldo_producing_adenoma_spec (?<!not\s|nor\s)aldo\w{0,7}([-\s]producing)?([-\s]ade)?noma
adrenal_adenoma adrenal adenoma
htn (?<!pulmonary\s)(?<!pulmonary arterial\s)(htn\b|hypertension)
htn_spec (?<!pulmonary\s)(?<!pulmonary arterial\s)(?<!not\s|nor\s)(htn\b|hypertension)
htn_teixera (?!pulm\w*\W*\w+\W+)\b(htn|hypertension)
relative_hyperaldo relative (hyper)?aldo
relative_hyperaldo_spec (?<!not\s|nor\s)relative (hyper)?aldo
salt_sensit salt sensiti
salt_sensit_spec (?<!not\s|nor\s)(?<!not indicate )(?<!not consistent with hyperaldosteronism or )(?<!not show )salt sensiti
adrenalectomy adrenalectomy
adrenalectomy_spec (?<!not\s|nor\s)adrenalectomy
word_count \b\w+\b
Table S2. Variable dictionary for the selected candidate predictors
Variable Missing1 Description
Demographics age 0 Age when aldosterone or renin test was performed (year)
gender 2 Gender
race 177 Race
hisp 69 Hispanic (Yes/No)
Pre-visit dbp 546 Diastolic blood pressure, from office visit closest (<= 14 days) to aldosterone/renin testing
sbp 546 Systolic blood pressure, from office visit closest (<= 14 days) to aldosterone/renin testing
time_bp_to_1st_RAR_yr 2392 Time interval (years) between first office visit with blood pressure recorded to aldosterone/renin test
time_enc_to_1st_RAR_yr 0 Time interval (years) between first clinical encounter to aldosterone/renin test
Laboratory data aldo 0 Serum aldosterone concentration (ng/dL)
pra 1168 Plasma renin activity (ng/mL/hr)
aldo:pra 1168 The aldosterone:renin ratio ((ng Aldosterone/dL)/(ng Angiotensin II/mL/hr))
test_potassium 1520 Blood potassium concentration (mmol/L)
test_sodium 1545 Blood sodium concentration (mmol/L)
test_carbon_dioxide 1548 Blood carbon dioxide concentration (mmol/L)
Encounter enc_n 0 Number of clinical encounters
enc_bp_n 0 Number of office visits with blood pressure recorded
time_bp_after_1st_RAR_yr 130 Time interval (years) between aldosterone/renin test and last office visit with blood pressure
time_enc_after_1st_RAR_yr 0 Time interval (years) between aldosterone/renin test and last clinical encounter
Diagnoses Dx_h2_E26.0_9_n 0
Sum of the number of encounters with primary aldosteronism diagnosis codes
(255.1, 255.10, 255.11, 255.12, E26.0, E26.01, E26.02, E26.09, E26.9)
Dx_h2_E26.1_8_n 0
Sum of the number of encounters with other hyperaldosteronism diagnosis codes
(255.13, 255.14, E26.1, E26.81, E26.89)
Notes re_hyperaldo 0 count of ’hyperaldo’ mentions in clinical notes
re_primaryaldo 0 count of ’primary aldo’ mentioned in the clinical notes
re_bah 0 count of ’bah’ mentioned in the clinical notes
re_adrenal_adenoma 0 count of ’adrenal_adenoma’ mentioned in the clinical notes
re_htn 0 count of ’hypertension’ mentioned in the clinical notes
re_adrenalectomy 0 count of ’adrenalectomy’ mentioned in the clinical notes
1: Number of patients with missing data on each variable among the 6319 patients.
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Table S3. Estimated odds ratio parameters when the phenotype prevalence was equal to 5%, 10%, 15%, or
20%.
Phenotype
prevalence β0 β1 β2 β3 β4 β5 β6 β7 β8 β9
5%
Mean -2.629 0.208 0.433 0.634 -1.053 -1.472 1.899 -2.112 2.545 2.952
Bias -0.129 0.008 0.033 0.034 -0.053 -0.072 0.099 -0.112 0.145 0.152
SE 0.561 0.061 0.353 0.122 0.135 0.391 0.240 0.253 0.463 0.357
ESE 0.573 0.062 0.368 0.127 0.144 0.416 0.258 0.269 0.476 0.383
10%
Mean 1.039 0.207 0.410 0.621 -1.031 -1.444 1.858 -2.067 2.482 2.895
Bias 0.039 0.007 0.010 0.021 -0.031 -0.044 0.058 -0.067 0.082 0.095
SE 0.471 0.046 0.267 0.092 0.101 0.294 0.181 0.189 0.345 0.268
ESE 0.486 0.047 0.271 0.091 0.106 0.301 0.192 0.197 0.350 0.284
15%
Mean 3.401 0.202 0.406 0.616 -1.023 -1.441 1.842 -2.049 2.461 2.868
Bias 0.101 0.002 0.006 0.016 -0.023 -0.041 0.042 -0.049 0.061 0.068
SE 0.517 0.040 0.232 0.079 0.088 0.255 0.157 0.163 0.299 0.232
ESE 0.520 0.041 0.237 0.082 0.091 0.258 0.166 0.171 0.308 0.237
20%
Mean 5.511 0.203 0.409 0.609 -1.019 -1.435 1.834 -2.039 2.443 2.856
Bias 0.111 0.003 0.009 0.009 -0.019 -0.035 0.034 -0.039 0.043 0.056
SE 0.583 0.036 0.209 0.072 0.079 0.231 0.143 0.148 0.270 0.211
ESE 0.562 0.036 0.214 0.072 0.078 0.227 0.141 0.144 0.268 0.210
Mean: the mean βˆ estimate; Bias: the difference between the mean βˆ and the true value of β; SE: the mean
asymptotic standard error estimate; ESE: the empirical standard error estimate
Table S4. Estimated cˆ and qˆ (95%CI) over 1000 replications. The logistic model was correctly specified
(”True Model”), with three weak predictors (”Misspecified − Model1”) omitted, or with three strong
predictors (”Misspecified−Model2”) omitted.
True Model Misspecified−Model1 Misspecified−Model2
c = 0.5, q = 0.1
ĉ 0.500 (0.459,0.541) 0.496 (0.451,0.541) 0.358 (0.142,0.574)
q̂ 0.100 (0.094,0.106) 0.101 (0.093,0.109) 0.221 (0.150,0.292)
c = 0.2, q = 0.1
ĉ 0.200 (0.167,0.233) 0.198 (0.163,0.233) 0.131 (0.001,0.270)
q̂ 0.101 (0.087,0.115) 0.101 (0.087,0.115) 0.364 (0.273,0.455)
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Table S5. Model-predicted vs. nonparametrically-estimated case numbers in the pre-defined intervals
of predicted probabilities for 10% phenotype prevalence. The logistic model was correctly specified
(”True Model”), with three weak predictors (”Misspecified − Model1”) omitted, or with three strong
predictors (”Misspecified − Model2”) omitted. Results are presented as the mean estimate over 1000
iterations.
TrueModel Misspecified −Model1 Misspecified −Model2
Interval
Model
predicted
Nonparametrically
estimated
Model
predicted
Nonparametrically
estimated
Model
predicted
Nonparametrically
estimated
0.0_0.1 13 15 18 19 140 163
0.1_0.2 13 14 16 18 197 234
0.2_0.3 13 14 17 18 160 192
0.3_0.4 14 15 18 18 122 149
0.4_0.5 16 16 20 20 92 113
0.5_0.6 19 18 23 22 68 88
0.6_0.7 23 22 28 26 49 64
0.7_0.8 30 29 36 34 35 49
0.8_0.9 47 45 54 52 24 37
0.9_1.0 313 312 278 281 296 161
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Table S6. Estimated vs. true predictive accuracy measures and their empirical standard errors of model
performance when the phenotype prevalence was equal to 5%, 10%, 15%, or 20%. Results are presented as
the mean estimate (the empirical standard error estimate).
Estimated predictive accuracy1 True predictive accuracy2
Phenotype
prevalence cutoff 0.20 0.30 0.40 0.50 0.20 0.30 0.40 0.50
5%
P̂PV
0.588 0.658 0.716 0.767 0.591 0.662 0.719 0.770
(0.056) (0.062) (0.069) (0.076) (0.036) (0.038) (0.041) (0.042)
T̂PR
0.925 0.892 0.858 0.822 0.925 0.892 0.859 0.822
(0.02) (0.025) (0.03) (0.036) (0.02) (0.025) (0.03) (0.036)
N̂PV
0.998 0.997 0.996 0.995 0.998 0.997 0.996 0.995
(0.001) (0.001) (0.001) (0.001) (0.001) (0.001) (0.001) (0.001)
F̂PR
0.017 0.012 0.009 0.007 0.017 0.012 0.009 0.007
(0.003) (0.002) (0.002) (0.002) (0.002) (0.002) (0.002) (0.002)
ÂUC
0.995 _ _ _ 0.995 _ _ _
(0.003) _ _ _ (0.001) _ _ _
10%
P̂PV
0.626 0.694 0.749 0.798 0.625 0.693 0.748 0.797
(0.043) (0.047) (0.051) (0.056) (0.026) (0.028) (0.028) (0.029)
T̂PR
0.942 0.914 0.884 0.852 0.942 0.914 0.885 0.852
(0.012) (0.016) (0.02) (0.024) (0.012) (0.016) (0.02) (0.024)
N̂PV
0.997 0.995 0.994 0.992 0.997 0.995 0.994 0.992
(0.001) (0.001) (0.001) (0.001) (0.001) (0.001) (0.001) (0.001)
F̂PR
0.031 0.022 0.017 0.012 0.032 0.023 0.017 0.012
(0.004) (0.004) (0.004) (0.003) (0.003) (0.003) (0.003) (0.002)
ÂUC
0.994 _ _ _ 0.993 _ _ _
(0.003) _ _ _ (0.001) _ _ _
15%
P̂PV
0.649 0.714 0.767 0.812 0.651 0.717 0.77 0.815
(0.035) (0.038) (0.041) (0.045) (0.021) (0.022) (0.023) (0.023)
T̂PR
0.951 0.926 0.900 0.870 0.951 0.927 0.900 0.870
(0.009) (0.012) (0.015) (0.018) (0.009) (0.012) (0.015) (0.019)
N̂PV
0.996 0.993 0.991 0.989 0.996 0.993 0.991 0.989
(0.001) (0.001) (0.001) (0.001) (0.001) (0.001) (0.001) (0.002)
F̂PR
0.045 0.032 0.024 0.018 0.045 0.032 0.024 0.017
(0.005) (0.005) (0.004) (0.004) (0.004) (0.003) (0.003) (0.003)
ÂUC
0.992 _ _ _ 0.992 _ _ _
(0.004) _ _ _ (0.001) _ _ _
20%
P̂PV
0.675 0.737 0.787 0.829 0.676 0.738 0.787 0.83
(0.03) (0.032) (0.034) (0.037) (0.019) (0.019) (0.019) (0.019)
T̂PR
0.959 0.938 0.914 0.887 0.959 0.937 0.914 0.887
(0.007) (0.01) (0.012) (0.014) (0.007) (0.009) (0.012) (0.014)
N̂PV
0.994 0.992 0.989 0.985 0.994 0.992 0.989 0.985
(0.001) (0.001) (0.001) (0.002) (0.001) (0.001) (0.002) (0.002)
F̂PR
0.059 0.043 0.032 0.023 0.059 0.043 0.032 0.023
(0.006) (0.006) (0.005) (0.005) (0.005) (0.004) (0.004) (0.003)
ÂUC
0.992 _ _ _ 0.991 _ _ _
(0.005) _ _ _ (0.001) _ _ _
1: predictive accuracy measures according to our proposed method
2: predictive accuracy measures when Y is truly observed
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Table S7. Predictive accuracy measures of model performance at 10% phenotype prevalence when c = 0.2.
Results are presented as the mean estimate (the empirical standard error estimate) over 1000 iterations.
Estimated predictive accuracy1 True predictive accuracy2
cutoff 0.20 0.30 0.40 0.50 0.20 0.30 0.40 0.50
P̂PV
0.728 0.779 0.818 0.851 0.727 0.779 0.819 0.852
(0.05) (0.051) (0.054) (0.058) (0.032) (0.034) (0.035) (0.036)
T̂PR
0.934 0.905 0.876 0.845 0.934 0.906 0.877 0.847
(0.023) (0.029) (0.035) (0.042) (0.016) (0.023) (0.029) (0.037)
N̂PV
0.994 0.992 0.989 0.986 0.994 0.992 0.989 0.986
(0.002) (0.002) (0.003) (0.003) (0.001) (0.002) (0.003) (0.003)
F̂PR
0.031 0.023 0.017 0.013 0.031 0.023 0.018 0.013
(0.006) (0.005) (0.005) (0.005) (0.005) (0.005) (0.005) (0.005)
ÂUC
0.994 _ _ _ 0.993 _ _ _
(0.006) _ _ _ (0.001) _ _ _
1: predictive accuracy measures according to our proposed method
2: predictive accuracy measures when Y is truly observed
Table S8. Estimated odds ratio parameters at 10% phenotype prevalence when c = 0.2.
β0 β1 β2 β3 β4 β5 β6 β7 β8 β9
Size of training set=10,000
Mean 1.192 0.220 0.453 0.664 -1.115 -1.573 2.029 -2.243 2.698 3.143
Bias 0.192 0.020 0.053 0.064 -0.115 -0.173 0.229 -0.243 0.298 0.343
SE 0.889 0.085 0.484 0.173 0.202 0.544 0.363 0.383 0.658 0.540
ESE 1.422 0.109 0.554 0.189 0.296 0.831 0.737 0.687 1.292 1.085
Size of training set=20,000
Mean 1.064 0.209 0.436 0.628 -1.044 -1.464 1.877 -2.087 2.495 2.925
Bias 0.064 0.009 0.036 0.028 -0.044 -0.064 0.077 -0.087 0.095 0.125
SE 0.577 0.055 0.320 0.111 0.123 0.354 0.220 0.230 0.416 0.327
ESE 0.594 0.056 0.334 0.117 0.125 0.351 0.226 0.237 0.403 0.332
Mean: the mean βˆ over 1000 iterations; Bias: the difference between the mean βˆ and the true value of β; SE:
the mean asymptotic standard error estimate; ESE: the empirical standard error.
Table S9. Model-predicted vs. nonparametrically-estimated case numbers in the pre-defined intervals of
predicted probabilities at 10% phenotype prevalence when c = 0.2. Results are presented as the mean estimate
over 1000 iterations.
Size of training set=10,000 Size of training set=20,000
Interval
Model
predicted
Nonparametrically
estimated
Model
predicted
Nonparametrically
estimated
0.0_0.1 20 29 21 25
0.1_0.2 19 23 20 22
0.2_0.3 20 23 21 23
0.3_0.4 22 23 23 23
0.4_0.5 25 25 26 26
0.5_0.6 29 27 30 29
0.6_0.7 35 33 36 35
0.7_0.8 46 43 48 46
0.8_0.9 72 66 74 71
0.9_1.0 515 508 503 502
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Table S10. Estimated (βˆ, cˆ1, cˆ2, qˆ) for stratified conditional independence with c1 = 0.2 and c2 = 0.8 at
10% phenotype prevalence.
β0 β1 β2 β3 β4 β5 β6 β7 β8 β9 c1 c2 q
Varying anchor sensitivity1
Mean 1.046 0.207 0.410 0.622 -1.031 -1.437 1.856 -2.062 2.478 2.882 0.201 0.800 0.100
Bias 0.046 0.007 0.010 0.022 -0.031 -0.037 0.056 -0.062 0.078 0.082 0.001 0.000 -0.000
ASE 0.559 0.041 0.238 0.081 0.089 0.262 0.159 0.165 0.459 0.234 0.025 0.022 0.004
ESE 0.577 0.040 0.243 0.082 0.091 0.258 0.161 0.168 0.476 0.237 0.025 0.022 0.004
Constant anchor sensitivity2
Mean -2.338 0.148 0.293 0.445 -0.735 -1.025 1.324 -1.471 4.827 2.047 0.712 _ 0.080
Bias -3.338 -0.052 -0.107 -0.155 0.265 0.375 -0.476 0.529 2.427 -0.753 0.212 _ -0.021
ASE 0.363 0.033 0.195 0.064 0.065 0.210 0.116 0.118 0.327 0.168 0.028 _ 0.004
ESE 0.504 0.034 0.200 0.071 0.077 0.212 0.138 0.145 0.349 0.209 0.036 _ 0.005
Mean: the mean estimates over 1000 iterations; Bias: the difference between the mean estimates and the true
values; SE: the mean asymptotic standard error estimate; ESE: the empirical standard error. 1: the fitted
model recognized the variation in anchor sensitivity; 2: the fitted model failed to recognize the variation in
anchor sensitivity.
Table S11. Model-predicted vs. nonparametrically-estimated case numbers in the pre-defined intervals of
predicted probabilities for stratified conditional independence with c1 = 0.2 and c2 = 0.8 at 10% phenotype
prevalence. Results are presented as the mean estimate over 1000 iterations.
Varying anchor sensitivity1 Constant anchor sensitivity2
Interval
Model
predicted
Nonparametrically
estimated
Model
predicted
Nonparametrically
estimated
0.0_0.1 6 6 5 6
0.1_0.2 6 6 4 4
0.2_0.3 6 6 5 4
0.3_0.4 6 6 5 4
0.4_0.5 7 7 5 5
0.5_0.6 8 8 6 6
0.6_0.7 10 9 7 7
0.7_0.8 13 13 9 9
0.8_0.9 21 19 13 13
0.9_1.0 134 138 59 57
1: the fitted model recognized the variation in anchor sensitivity
2: the fitted model failed to recognize the variation in anchor sensitivity
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Table S12. Estimated predictive accuracy measures of model performance for stratified conditional
independence with c1 = 0.2 and c2 = 0.8 at 10% phenotype prevalence. Results are presented as the mean
estimate (the empirical standard error).
Varying anchor sensitivity1 Constant anchor sensitivity2
cutoff 0.20 0.30 0.40 0.50 0.20 0.30 0.40 0.50
True predictive accuracy3
P̂PV
0.589 0.66 0.719 0.771 0.571 0.647 0.717 0.781
(0.036) (0.037) (0.037) (0.037) (0.038) (0.039) (0.041) (0.041)
T̂PR
0.938 0.908 0.879 0.845 0.684 0.618 0.565 0.516
(0.022) (0.028) (0.033) (0.038) (0.065) (0.066) (0.066) (0.066)
N̂PV
0.997 0.995 0.994 0.992 0.985 0.982 0.979 0.977
(0.001) (0.001) (0.002) (0.002) (0.003) (0.003) (0.003) (0.003)
F̂PR
0.032 0.023 0.017 0.012 0.025 0.016 0.011 0.007
(0.004) (0.004) (0.003) (0.003) (0.003) (0.003) (0.002) (0.002)
ÂUC
0.993 0.993 0.993 0.993 0.976 0.976 0.976 0.976
(0.001) (0.001) (0.001) (0.001) (0.006) (0.006) (0.006) (0.006)
Estimated predictive accuracy4
P̂PV
0.594 0.668 0.729 0.785 0.401 0.484 0.561 0.633
(0.048) (0.055) (0.062) (0.068) (0.061) (0.068) (0.076) (0.088)
T̂PR
0.944 0.918 0.889 0.858 0.910 0.873 0.835 0.790
(0.015) (0.018) (0.021) (0.024) (0.021) (0.026) (0.03) (0.036)
N̂PV
0.997 0.996 0.995 0.993 0.998 0.997 0.996 0.995
(0.001) (0.001) (0.001) (0.001) (0.001) (0.001) (0.001) (0.001)
F̂PR
0.031 0.022 0.016 0.012 0.034 0.023 0.016 0.011
(0.005) (0.004) (0.004) (0.004) (0.004) (0.004) (0.003) (0.003)
ÂUC
0.995 _ _ _ 0.990 _ _ _
(0.003) _ _ _ (0.003) _ _ _
1: the fitted model recognized the variation in anchor sensitivity
2: the fitted model failed to recognize the variation in anchor sensitivity
3: predictive accuracy measures when Y is truly observed
4: predictive accuracy measures according to our proposed method
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Table S13. Estimated cˆ (SE), qˆ (SE) and ÂUC for the series of models in model training - Anchor 1
Covariates cˆ (SE) qˆ (SE) ÂUC
Demographics+pre_visit age,gender,race,hisp,dbp,sbp, 0.104 (0.020) 0.302 (0.054) 0.787
time_enc_to_1st_RAR,time_bp_to_1st_RAR
+Laboratory data +aldo,aldo:pra,test_potassium, 0.577 (0.119) 0.047 (0.010) 0.897
test_sodium,test_carbon_dioxide
+Encounters +enc_n,enc_bp_n,time_enc_after_1st_RAR, 0.64 (0.131) 0.054 (0.011) 0.919
time_bp_after_1st_RAR
+Diagnoses +Dx_h2_E26.0_9_n,Dx_h2_E26.1_8_n 0.486 (0.068) 0.071 (0.010) 0.963
+Notes +re_hyperaldo,re_primaryaldo,re_bah, 0.451 (0.041) 0.077 (0.007) 0.994
re_adrenal_adenoma,re_htn,re_adrenalectomy
Final_model age, aldo, aldo:pra, test_potassium, test_sodium, 0.374 (0.047) 0.076 (0.008) 0.993
dbp,enc_bp,time_enc_after_1st_RAR,
re_hyperaldo,re_adrenalectomy
SE: Asymptotic standard error
Table S14. Estimated cˆ (SE), qˆ (SE) and ÂUC for the series of models in model training - Anchor 2
Covariates cˆ (SE) qˆ (SE) ÂUC
Demographics+pre_visit age,gender,race,hisp,dbp,sbp, 0.148 (0.025) 0.268 (0.041) 0.780
time_enc_to_1st_RAR,time_bp_to_1st_RAR
+Laboratory data +aldo,aldo:pra,test_potassium, 0.744 (0.107) 0.049 (0.008) 0.897
test_sodium,test_carbon_dioxide
+Encounters +enc_n,enc_bp_n,time_enc_after_1st_RAR, 0.769 (0.114) 0.058 (0.009) 0.914
time_bp_after_1st_RAR
+Diagnoses +Dx_h2_E26.0_9_n,Dx_h2_E26.1_8_n 0.541 (0.065) 0.082 (0.010) 0.972
+Notes +re_hyperaldo,re_primaryaldo,re_bah, 0.562 (0.041) 0.079 (0.006) 0.993
re_adrenal_adenoma,re_htn,re_adrenalectomy
Final_model aldo, aldo:pra, test_potassium, test_sodium, 0.552 (0.042) 0.070 (0.006) 0.993
enc,enc_bp,time_bp_after_1st_RAR,Dx_h2_E26.0_9_n
re_hyperaldo,re_primaryaldo,re_bah,
re_adrenal_adenomare_adrenalectomy
SE: Asymptotic standard error
Table S15. Final model - Anchor 1
Intercept age aldo aldo:pra po so dbp enc_bp
time_enc_after_
1st_RAR_yr
re_
hyperaldo
re_
adrenalectomy
LogOR -6.36 -0.37 1.03 1.64 0.20 0.68 -0.57 -1.83 1.07 3.98 1.24
SE 0.69 0.30 0.40 0.37 0.27 0.27 0.28 0.39 0.27 1.00 0.36
p value 0.00 0.22 0.01 0.00 0.46 0.01 0.04 0.00 0.00 0.00 0.00
SE: Asymptotic standard error
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Table S16. Final model - Anchor 2
Intercept aldo aldo:pra po so enc enc_bp
time_bp_after_
1st_RAR_yr hyperh260
re_
hyperaldo
LogOR -6.46 0.99 1.10 0.20 0.25 -0.11 -2.12 0.98 1.36 2.01
SE 0.68 0.35 0.34 0.26 0.29 0.66 0.66 0.35 0.40 0.83
p value 0.00 0.00 0.00 0.44 0.39 0.87 0.00 0.00 0.00 0.02
re_
primary_aldo
re_
bah
re_
adenoma
re_
adrenalectomy
LogOR 0.54 2.23 0.90 1.26
SE 0.28 0.83 0.27 0.37
p value 0.06 0.01 0.00 0.00
SE: Asymptotic standard error
Table S17. Characteristics of patients
Final population (N = 3579) Rest (N = 2740)
Age1 55 (16) 54 (16)
Gender
Male (%) 1420 (40) 1053 (38)
Female (%) 2159 (60) 1687 (62)
Race
Caucasian (%) 1760 (50) 1510 (57)
African-American (%) 1510 (43) 930 (35)
Other (%) 234 (7) 234 (8)
Aldosterone2 (ng/DL) 8.0 (4.5-14.9) 8.0 (4.4-14.3)
Renin2 (ng/mL/hr) 0.9 (0.3-2.8) 0.9 (0.3-2.6)
Aldo : Renin2 8.0 (2.6-28.2) 8.4 (2.9-26.4)
Potassium1 (mmol/L) 4.1 (0.6) 4.1 (0.6)
Sodium1 (mmol/L) 139 (3.0) 139(3.5)
CO21 (mmol/L) 26.7 (3.0) 26.3 (4.1)
1: Mean (SD), 2: Median (IQR)
Table S18. Model-predicted vs. nonparametrically-estimated case numbers in the pre-defined intervals of
predicted probabilities for the baseline models.
Anchor 1 Anchor 2
Interval Model − predicted Nonparametrically − estimated Model − predicted Nonparametrically − estimated
0.0_0.1 39 51 44 52
0.1_0.2 121 111 139 132
0.2_0.3 160 137 155 160
0.3_0.4 160 154 135 97
0.4_0.5 138 154 96 109
0.5_0.6 114 103 75 103
0.6_0.7 74 86 38 40
0.7_0.8 43 69 18 6
0.8_0.9 17 26 7 17
0.9_1.0 74 77 35 63
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